Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：2

作者：

Spencer, Andrew ^{[1
]}

Iversen, Katrine Fladeland ^{[2
]}

Dhakal, Binod ^{[3
]}

Creignou, Maria ^{[4
]}

Chen, Jenny ^{[5
]}

Hiemstra, Ida H. ^{[6
]}

Bosgra, Sieto ^{[6
]}

Badani, Avani ^{[5
]}

Breij, Esther C. W. ^{[6
]}

Brady, Lauren K. ^{[5
]}

Sasser, A. Kate ^{[5
]}

Malmberg, Anders ^{[7
]}

Gregersen, Henrik ^{[8
]}

Hansson, Markus ^{[9
]}

Broijl, Annemiek ^{[10
]}

Mateos, Maria-Victoria ^{[11
]}

Plesner, Torben ^{[2
]}

机构：

[1] Alfred Hosp, Melbourne, Vic, Australia

[2] Vejle Hosp, Vejle, Denmark

[3] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA

[4] Karolinska Univ Hosp, Dept Hematol, Huddinge, Sweden

[5] Genmab, Princeton, NJ USA

[6] Genmab, Utrecht, Netherlands

[7] Genmab, Copenhagen, Denmark

[8] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark

[9] Aalborg Univ Hosp, Aalborg, Denmark

[10] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[11] USAL CSIC, Hosp Univ Salamanca, IBSAL, IBMCC, Salamanca, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7320 / 7321

页数：2

共 50 条

[31] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
Jing, Hongmei
Yang, Li
Qi, Junyuan
Qiu, Lugui
Fu, Chengcheng
Li, Junmin
Yang, Min
Qi, Ming
Fan, Ni
Ji, Jia
Lu, Jiajia
Li, Yunan
Jin, Jie
ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2679 - 2690
[32] Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Yee, Andrew J.
Laubach, Jacob P.
Nooka, Ajay K.
O'Donnell, Elizabeth K.
Weller, Edie A.
Couture, Nicole R.
Wallace, Ellen E.
Burke, Jill N.
Harrington, Cynthia C.
Puccio-Pick, Marie
Laadem, Abderrahmane
Sherman, Matthew L.
Raje, Noopur S.
BLOOD, 2015, 126 (23)
[33] A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
Berenson, James R.
Klein, Leonard
Rifkin, Robert M.
Patel, Priti
Dixon, Sandra
Ou, Ying
Cartmell, Alan
BLOOD, 2013, 122 (21)
[34] Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Krishnan, Amrita Y.
Patel, Krina K.
Hari, Parameswaran
Jagannath, Sundar
Niesvizky, Ruben
Silbermann, Rebecca W.
Berg, Deborah
Lin, Jianchang
Fedyk, Eric Robert
Palumbo, Antonio
Stockerl-Goldstein, Keith E.
BLOOD, 2019, 134
[35] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Kropff, Martin
Kienast, Joachim
Bisping, Guido
Berdel, Wolfgang E.
Gaschler-Markefski, Birgit
Stopfer, Peter
Stefanic, Martin
Munzert, Gerd
ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
[36] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Ghobrial, Irene M.
Weller, Edie
Vij, Ravi
Munshi, Nikhil C.
Banwait, Ranjit
Bagshaw, Meghan
Schlossman, Robert
Leduc, Renee
Chuma, Stacey
Kunsman, Janet
Laubach, Jacob
Jakubowiak, Andrzej J.
Maiso, Patricia
Roccaro, Aldo
Armand, Philippe
Dollard, Akari
Warren, Diane
Harris, Brianna
Poon, Tiffany
Sam, Amy
Rodig, Scott
Anderson, Kenneth C.
Richardson, Paul G.
LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
[37] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
Stiff, Patrick J.
Maharaj, Michele
Oliver, Katherine
Callander, Natalie Scott
BLOOD, 2016, 128 (22)
[38] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
Chari, Ajai
Usmani, Saad Zafar
Mateos, Maria-Victoria
Van De Donk, Niels
Kaufman, Jonathan L.
Moreau, Philippe
Rocafiguera, Albert Oriol
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara J.
Clemens, Pamela L.
Farnsworth, Andrew
Nahi, Hareth
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[39] Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).
Wong, Lilly
Jimenez Nunez, Maria Dolores
Bahlis, Nizar J.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Wang, Maria
Lamba, Manisha
Pourdehnad, Michael
Pierce, Daniel W.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
San Miguel, J.
Sezer, O.
Siegel, D.
Guenther, A.
Blade, J.
Prosser, I.
Hazell, K.
Bengoudifa, R.
Klebsattel, M.
Bourquelot, P.
Cavo, M.
Goebeler, M.
Niederweiser, D.
Milder, M.
Boccadoro, M.
Anderson, K.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155

← 1 2 3 4 5 →